Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Ph+ ALL
NCT04722848Phase 3Active, not recruiting
- Sponsor
- GIMEMA
- Start
- Sep 2021
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ponatinib and blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Started Sep 2021; status: active, not recruiting.
02
Drugs
ponatinibblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04722848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722848.